The compound was introduced as a legal alternative by incorporating a trimethylsilyl group, which is not covered under current NpSG regulations. This chemical modification allows 1S-LSD to be legally sold in Germany as of September 2024. It is typically distributed in its hemi-D-tartrate form, a common format for lysergamides due to its stability and ease of use.[5]
The dose of 1S-LSD is reported to be similar to that ofLSD.[2]Blotter tabs containing 129μg 1S-LSD have been encountered.[2] 1S-LSD is thought to be aprodrug and produces similar effects as LSD and other LSD prodrugs.[2]
While specific studies on 1S-LSD are limited due to its recent introduction, it is presumed to share pharmacological properties with LSD and its analogues. These substances typically act as partial agonists atserotonin receptors, particularly theserotonin5-HT2A receptor, which is responsible for their hallucinogenic effects. The addition of the trimethylsilyl group in 1S-LSD is thought to slightly alter its binding affinity and metabolic profile, although empirical data is still needed.[7]
1S-LSD belongs to the lysergamide class of compounds, which are characterized by theergoline structure derived from lysergic acid. The compound is closely related to LSD and 1P-LSD but differs by the addition of a trimethylsilyl group on the propionyl chain.
The nitrogen atom in the polycyclic indole group of the ergoline structure is a common site for chemical modifications, as it is highly reactive and accessible for various reactions. These modifications often includealkylations,acylations,Mannich reactions, andMichael additions. Such alterations are frequently explored in the synthesis of new analogues to modify pharmacological properties or evade legal controls. The addition of the trimethylsilyl group in 1S-LSD represents a strategic modification designed to keep the substance outside the coverage of Germany's New Psychoactive Substances Act (NpSG). Despite these changes, 1S-LSD likely retains a pharmacological profile similar to that of LSD, acting primarily as a serotonergic hallucinogen.[8][9][10]
As of August 2024, 1S-LSD remains legal in Germany, primarily due to the fact that its unique silicon-containing structural alteration circumvent the legislative controls imposed by the NpSG law. The legal status of 1S-LSD in Germany is likely subject to change with future amendments to the NpSG, similarly to its previously banned sister compounds1V-LSD and1D-LSD. However, it is anticipated that 1S-LSD will remain legal at least until mid-2025.[5][6]An update on the 21st of November 2025 added 1S-LSD to the "NpSG" made the sale illegal in Germany ("sechste Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes (NpSG)").
The legal status of 1S-LSD outside of Germany is not well-documented. Given its structural similarity to LSD, it may be considered a controlled substance analogue in jurisdictions like the United States, where laws like the Federal Analogue Act could apply. Potential users and researchers should verify the legal status of 1S-LSD in their respective countries before acquisition or use.[7]
^"1S-LSD".АИПСИН (in Russian). Retrieved1 January 2026.
^abcde"1S-LSD".АИПСИН (in Russian). Retrieved6 January 2026.
^WO 2024/028495, Stratford A, Williamson JP, "Prodrugs of Substituted Ergolines", published 8 February 2024, assigned to Synex Holdings BV
^Tanaka R, Kawamura M, Ito M, Kikura-Hanajiri R (July 2025). "Identification of two lysergic acid diethylamide analogs, 1-(3-(trimethylsilyl) propionyl) lysergic acid diethylamide (1S-LSD) and 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD), in paper sheet products distributed on the internet".Forensic Toxicology.43 (2):370–376.doi:10.1007/s11419-025-00718-3.PMID40180768.
